Median Technologies Stock

Equities

ALMDT

FR0011049824

Advanced Medical Equipment & Technology

Market Closed - Euronext Paris 11:35:17 2024-05-24 am EDT 5-day change 1st Jan Change
3.7 EUR -1.20% Intraday chart for Median Technologies +8.82% -22.11%
Sales 2024 * 25.05M 27.17M Sales 2025 * 45.82M 49.7M Capitalization 68.06M 73.81M
Net income 2024 * -24M -26.03M Net income 2025 * -19M -20.61M EV / Sales 2024 * 3.67 x
Net Debt 2024 * 23.75M 25.76M Net Debt 2025 * 41.3M 44.79M EV / Sales 2025 * 2.39 x
P/E ratio 2024 *
-2.97 x
P/E ratio 2025 *
-3.64 x
Employees 256
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.99%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.20%
1 week+8.82%
Current month+42.58%
1 month+12.12%
3 months-3.39%
6 months-10.19%
Current year-22.11%
More quotes
1 week
3.24
Extreme 3.235
3.85
1 month
2.50
Extreme 2.5
3.85
Current year
2.33
Extreme 2.325
5.06
1 year
2.33
Extreme 2.325
6.77
3 years
2.33
Extreme 2.325
18.32
5 years
0.93
Extreme 0.93
18.32
10 years
0.90
Extreme 0.9
18.32
More quotes
Managers TitleAgeSince
Founder 62 01-12-31
Director of Finance/CFO - 21-07-11
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 70 20-06-24
Chairman 62 08-03-25
Director/Board Member 67 15-11-29
More insiders
Date Price Change Volume
24-05-24 3.7 -1.20% 48,499
24-05-23 3.745 +7.61% 148,943
24-05-22 3.48 +2.65% 199,391
24-05-21 3.39 -5.31% 39,339
24-05-20 3.58 +5.29% 65,855

Real-time Euronext Paris, May 24, 2024 at 11:35 am EDT

More quotes
Median Technologies offers innovative imaging solutions and services to improve healthcare for all. The group uses the power of phenomic imaging to contribute to the emergence of new therapies and treatment strategies for patients. Its solutions, «iSee» for the image management in oncology trials and «iBiopsy», its phenomic imaging platform, combined with the expertise of its teams are an essential part to the discovery of new drugs and diagnostic tools to monitor diseases and evaluate the response of patients to their therapy. Median Technologies is helping biopharmaceutical companies and healthcare professionals quickly and accurately introduce new treatments to patients who need them, with a view to reducing overall costs of care. Provision of services accounts for all net sales. Net sales are distributed geographically as follows: France (4%), the United States and Canada (37%), China (19.2%), the United Kingdom (18.9%) and other (20.9%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.7 EUR
Average target price
24.18 EUR
Spread / Average Target
+553.38%
Consensus

Annual profits - Rate of surprise